NEW YORK, April 10, 2008 (PRIME NEWSWIRE) -- Manhattan Pharmaceuticals, Inc. (OTCBB:MHAN) announced today that it has completed patient enrollment in its ongoing Phase 2a clinical study of Topical PTH (1-34). This randomized, double-blind, vehicle-controlled, parallel group study is designed to evaluate safety and preliminary efficacy of Topical PTH (1-34) for the treatment of psoriasis. The study randomized 61 patients into three treatment groups (two dose levels of Topical PTH (1-34) and one vehicle only group) for an 8-week treatment period at four U.S. clinical trial sites. The vehicle used in this study is the topical product without the active ingredient, PTH (1-34). The company expects to announce the results of this study in summer 2008.
